By contrast, sodium channel blockers usually exacerbate seizures in patients with Dravet syndrome, which is caused by a deficiency of SCN1A activity. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.